Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX0205	Email from Ted Smolenski to Joyce De Los Reyes, Kevin Sica, Todd Engle, et al. re: Endo: One Deal Away from Being Interesting w/Attach: ENDP--UBS--2010-02-22.pdf	2/23/2010	IMPAX-OPANA-CID00020815	IMPAX-OPANA-CID00020832	GX0205; RX-396	JX-002			
CX0206	Email from Ted Smolenski to June Hughes re: Oxymne GM %	5/6/2010	IMPAX-OPANA-CID00018218	IMPAX-OPANA-CID00018218	GX0206	JX-002			
CX0207-CX0210	Intentionally Not Used					N/A			
CX0211	Email from Ted Smolenski to Meg Snowden, Chris Mengler, Huong Nguyen, et al. re: Impax - Endo w/Attach: Opana ER CAGR 2010-06-07.xlsx	6/7/2010	IMPAX-OPANA-CID00021881	IMPAX-OPANA-CID00021884	GX0211	JX-002			
CX0212-CX0213	Intentionally Not Used					N/A			
CX0214	Email from Ted Smolenski to Larry Hsu, Chris Mengler re: Research Notes - ENDO First Settlement for Generic Opana ER	2/23/2009	IMPAX-OPANA-CID00020833	IMPAX-OPANA-CID00020833	GX0214; RX-397	JX-002			
CX0215	Intentionally Not Used					N/A			
CX0216	Email from Ted Smolenski to Chris Mengler, David Berman re: opana ER	5/27/2010	IMPAX-OPANA-CID00006048	IMPAX-OPANA-CID00006048	GX0216; GX0110	JX-002			
CX0217	Email from Chris Mengler to Ted Smolenski re: Oxymorphone	6/2/2010	IMPAX-OPANA-CID00019449	IMPAX-OPANA-CID00019450	GX0217; GX0113; RX-389	JX-002			
CX0218	Email from Ted Smolenski to Chris Mengler re: No Subject	6/7/2010	IMPAX-OPANA-CID00019477	IMPAX-OPANA-CID00019477	GX0218; RX-391	JX-002			
CX0219	Email from Ted Smolenski to Larry Hsu, Art Koch re: opana ER	1/8/2011	IMPAX-OPANA-CID00003537	IMPAX-OPANA-CID00003538	GX0219	JX-002			
CX0220-CX0221	Intentionally Not Used					N/A			
CX0222	Email from Ted Smolenski to Kevin Sica, June Hughes, and Larry Kloss re: 5-year forecast 2010-May Update 2010--05- 14v5.xls w/Attach: 5-year forecast 2010-May Update 2010--05- 14v5.xls	5/15/2010	IMPAX-OPANA-CID00007067	IMPAX-OPANA-CID00007068	GX0222	JX-002			
CX0223-CX0300	Intentionally Not Used					N/A			
CX0301	FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, Application No N21610	9/24/2014	CX0301-001	CX0301-001	GX0301; GX0401	JX-002			Tr. 350:02; 350:05
CX0302	Email from Huong Nguyen to Art Koch, Meg Snowden, echoy@wsgr.com re: Draft Impax/Endo/Penwest Settlement and License Agreement w/Attach: Impax - Endo Settlement Agreement (Opana) [Execution Version].DOC	6/7/2010	IMPAX-OPANA-CID00007031	IMPAX-OPANA-CID00007057	GX0302; RX-338	JX-002			
CX0303	Case 2:09-cv-00831-KSH-PS: Com								

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX0320	Email from Guy Donatiello to Chris Mengler, Meg Snowden, Alan Levin, et al. re: Highly Confidential - Rule 408 Settlement Communication w/Attach: Endo - Impax - Development Term Sheet (5-26-2010).DOC; Endo - Impax - Settlement Term Sheet(5-26-2010).docx	5/26/2010	IMPAX-OPANA-CID00001716	IMPAX-OPANA-CID00001726	GX0320; GX0403; GX0109; RX-276	JX-002			Tr. 427:04; 427:10; 488:23; 489:06
CX0321	Email from Alan Levin to Chris Mengler, Meg Snowden, Guy Donatiello re: Highly Confidential - Rule 408 Settlement Communication	5/30/2010	IMPAX-OPANA-CID00005952	IMPAX-OPANA-CID00005954	GX0321; GX0111	JX-002			Tr. 538:18; 538:20; 539:01
CX0322	Intentionally Not Used					N/A			
CX0323	Email from Guy Donatiello to Meg Snowden, Chris Mengler, Alan Levin, et al. re: <no subject> w/Attach: Draft Impax - Endo Settlement and License Agreement.DOC	6/4/2010	IMPAX-OPANA-CID00001693	IMPAX-OPANA-CID00001715	GX0323; GX0409; GX1210; RX-275	JX-002			
CX0324	Email from Eliot Choy to Alan Levin, Guy Donatiello, Martin Black, et al. re: Impax - Endo w/Attach: 639178_Result.rtf; Impax - Endo - Rider to Settlement Agreement_(PALIB1_3993057_1).DOC; Impax - Endo - Settlement Agreement_(PALIB1_3992129_3).DOC	6/5/2010	IMPAX-OPANA-CID00001738	IMPAX-OPANA-CID00001783	GX0324; GX0413; GX1812; RX-279	JX-002			Tr. 147:15
CX0325	Intentionally Not Used					N/A			
CX0326	Email from Alison Freeman-Gleason to Justin Watkins, Meg Snowden, Alan Levin, et al. re: Co-Promote Revisions w/Attach: Impax-Endo_Development_and_Co-Promotion_Agreement_final.pdf; et al.	6/7/2010	IMPAX-OPANA-CID00011838	IMPAX-OPANA-CID00011904	GX0326; GX0417; RX-357	JX-002			
CX0327	Email from Robert Cooper to Steve Mollichella, Guy Donatiello, Meg Snowden, et al. re: Upfront payment	6/24/2010	IMPAX-OPANA-CID00003054	IMPAX-OPANA-CID00003055	GX0327	JX-002			
CX0328	Email from Meg Snowden to Guy Donatiello re: Endo/Opana	10/7/2010	IMPAX-OPANA-CID00005749	IMPAX-OPANA-CID00005749	GX0328; RX-314	JX-002			
CX0329	Email from Meg Snowden to Guy Donatiello re: steering committee	12/16/2010	IMPAX-OPANA-CID00002274	IMPAX-OPANA-CID00002275	GX0329; RX-286	JX-002			
CX0330	Email from Guy Donatiello to Chris Mengler, Meg Snowden, Caroline Manogue re: Letter from Endo to Impax Labs w/Attach: img-Z27121156-0001.pdf	12/27/2012	IMPAX-OPANA-CID00012058	IMPAX-OPANA-CID00012060	GX0330; GX1214; GX1822; RX-361	JX-002			
CX0331	Letter from Margaret Snowden to Caroline Manogue re: Settlement and License Agreement of June 8, 2010 Made By and Among Endo Pharmaceuticals Inc., Penwest Pharmaceuticals Co., and Impax Laboratories, Inc.	1/3/2013	IMPAX-OPANA-CID00000322	IMPAX-OPANA-CID00000322	GX0331	JX-002			
CX0332	Email from Huong Nguyen to Guy Donatiello, Meg Snowden re: Settlement and License Agreement by Endo, Penwest, and Impax ("License Agreement") w/Attach: Copy of Endo Credit Calculation (2).xlsx; DOC.PDF	1/22/2013	IMPAX-OPANA-CID00005750	IMPAX-OPANA-CID00005765	GX0332; RX-315	JX-002			Tr. 387:12; 436:16; 490:19
CX0333	Email from Brad Lucas to Dacia Kutnyak, Accounts Receivable, Robin Rieben, et al. re: Endo Deposit - 04/18/2013 - $102,049,199.64	4/18/2013	IMPAX-OPANA-CID00000275	IMPAX-OPANA-CID00000277	GX0333	JX-002			
CX0334-CX0405	Intentionally Not Used					N/A			
CX0406	Email from Chris Mengler to Larry Hsu, Art Koch, Michael Nestor, et al. re: <no subject>	6/2/2010	IMPAX-OPANA-CID00019448	IMPAX-OPANA-CID00019448	GX0406	JX-002			
CX0407	Email from Art Koch to Chris Mengler, Larry Hsu, Chuck Hildenbrand, et al. re: Status	6/3/2010	IMPAX-OPANA-CID00011819	IMPAX-OPANA-CID00011820	GX0407; RX-356	JX-002			Tr. 543:15; 543:22
CX0408-CX0409	Intentionally Not Used					N/A			
CX0410	Email from Alan Levin to Art Koch, Guy Donatiello, Meg Snowden, et al. re: <no subject>	6/4/2010	IMPAX-OPANA-CID00001592	IMPAX-OPANA-CID00001596		JX-002			
CX0411	Email from Guy Donatiello to Meg Snowden, Art Koch, Alan Levin re: Revised Draft #2 w/Attach: #710157v3_BE01_ - Impax- Co-Promotion Agreement.DOC	6/4/2010	IMPAX-OPANA-CID00006365	IMPAX-OPANA-CID00006394	GX0408; RX-280	JX-002			
CX0412-CX0414	Intentionally Not Used					N/A			
CX0415	Email from Alan Levin to Art Koch, Meg Snowden, Larry Hsu, et al. re: Endo/Impax: R&D Collaboration	6/6/2010	IMPAX-OPANA-CID00001727	IMPAX-OPANA-CID00001728	GX0415; RX-277	JX-002			
CX0416	Email from Art Koch to Alan Levin, Meg Snowden, Guy Donatiello, et al. re: Gross Margin	6/6/2010	IMPAX-OPANA-CID00001815	IMPAX-OPANA-CID00001815	GX0416; GX0510; RX-281	JX-002			
CX0417	Intentionally Not Used					N/A			

IN THE MATTER OF IMPAX
DOCKET NO. 9373

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX0418	Email from Thomas Rayski to Huong Nguyen, Guy Donatiello, Jennifer Saionz, et al. re: Draft Impax/Endo/Penwest Settlement and License Agreement w/Attach: Impax - Endo Settlement Agreement (Opana) [Execution Versioin].DOC: Redline.pdf	6/7/2010	IMPAX-OPANA-CID00001910	IMPAX-OPANA-CID00001960	GX0418	JX-002			
CX0419-CX0420	Intentionally Not Used					N/A			
CX0421	Email from Chuck Hildenbrand to Art Koch re: Impax: Inventory Carrying Value - June 30, 2010 - OXM w/Attach: Oxymorphone Expiration Dates	6/21/2010	IMPAX-OPANA-CID00008018	IMPAX-OPANA-CID00008025	GX0421; RX-345	JX-002			
CX0422	Email from Jennifer Hsu to Leslie Benet, Allen Chao, Art Koch, et al. re: BOD Monthly Update -- June 2010 - CONFIDENTIAL w/Attach: BOD Monthly Update June 2010 072310.doc	7/23/2010	IMPAX-OPANA-CID00018515	IMPAX-OPANA-CID00018542	GX0422	JX-002		Ordered 10/23/2017	
CX0423	Email from Mark Donohue to Chris Mengler, Larry Hsu, Art Koch, et al. re: Courtesy of Business Wire: - Endo, Penwest settle patent lawsuits over painkiller	6/8/2010	IMPAX-OPANA-CID00021058	IMPAX-OPANA-CID00021059	GX0423	JX-002			
CX0424	Intentionally Not Used					N/A			
CX0425	Impax Annual Report 2013: Focusing on Quality and Growth (December 31, 2013 SEC Form 10-K)	2/24/2014	CX0425-001	CX0425-157	GX0425	JX-002			Tr. 1206:09, 10, 14, 24; 1207:12
CX0426-CX0501	Intentionally Not Used					N/A			
CX0502	Email from Michael Nestor to Chris Mengler, Larry Hsu, Meg Snowden re: <no subject>	5/26/2010	IMPAX-OPANA-CID00019432	IMPAX-OPANA-CID00019432	GX0502; GX0108; GX0318	JX-002			
CX0503-CX0504	Intentionally Not Used					N/A			
CX0505	Email from Chris Mengler to Larry Hsu re: Mengler Board Slides	5/14/2010	IMPAX-OPANA-CID00007101	IMPAX-OPANA-CID00007102	GX0505; GX0104	JX-002			
CX0506	Email from Chris Mengler to Michael Nestor, Larry Hsu, Meg Snowden, et al. re: Today's Meeting	6/2/2010	IMPAX-OPANA-CID00019444	IMPAX-OPANA-CID00019445	GX0506; GX0112; GX0405	JX-002			Tr. 540:24; 541:24; 3031:09
CX0507	Email from Larry Hsu to Chris Mengler re: Status	6/4/2010	IMPAX-OPANA-CID00018248	IMPAX-OPANA-CID00018250	GX0507; GX0115	JX-002			
CX0508-CX0512	Intentionally Not Used					N/A			
CX0513	Email from Meg Snowden to Larry Hsu, Chris Mengler, Chuck Hildenbrand, et al. re: Oxymorphone ER Tablets Tentatively Approved Today!!	5/13/2010	IMPAX-OPANA-CID00018243	IMPAX-OPANA-CID00018243	GX0513; GX0419; GX0103; GX0313	JX-002			
CX0514	Email from Chris Mengler to Larry Hsu, Art Koch, Michael Nestor, et al. re: 5-year forecast 2010-May Update with Impax.xls w/Attach: 5-year forecast 2010-May Update with Impax.xls	5/16/2010	IMPAX-OPANA-CID00006712	IMPAX-OPANA-CID00006713	GX0514; GX0420; RX-330	JX-002			Tr. 49:24
CX0515	Email from Larry Hsu to Laura Bisbing, Jennifer Hsu re: Mengler Board Slides w/Attach: Mengler Board Presentation Aug10 080510b.ppt	8/8/2010	IMPAX-OPANA-CID00012917	IMPAX-OPANA-CID00012959	GX0515	JX-002		Ordered 10/23/2017	
CX0516	Intentionally Not Used					N/A			
CX0517	Email from Meg Snowden to Larry Hsu, Carole Ben-Maimon, Mark Donohue, et al. re: Letter from Endo to Impax Labs	12/29/2012	IMPAX-OPANA-CID00021673	IMPAX-OPANA-CID00021676	GX0517; RX-404	JX-002			
CX0518	Intentionally Not Used					N/A			
CX0519	Email from Carole Ben-Maimon to Larry Hsu re: Oxymorphone	1/5/2013	IMPAX-OPANA-CID00019290	IMPAX-OPANA-CID00019293	GX0519	JX-002			
CX0520	Intentionally Not Used					N/A			
CX0521	Impax Presentation: IMPAX Pharmaceuticals R&D Update	2/26/2014	IMPAX-OPANA-CID00019495	IMPAX-OPANA-CID00019542	GX0521	JX-002		Ordered 10/23/2017	
CX0522-CX1000	Intentionally Not Used					N/A			
CX1001	Endo Presentation: Corporate Development Update: Endo Board of Directors Meeting	2/24/2010	EPI000821205	EPI000821205	GX1001; RX-041	JX-002			Tr. 2580:17; 2580:19; 2580:22; 2581:15; 2581:21; 2582:05
CX1002	Endo Presentation: Corporate Development & Strategy Departmental Offsite	3/7/2010	EPI001305772	EPI001305772	GX1002	JX-002			Tr. 2582:16; 2582:19; 2582:22; 2583:08
CX1003-CX1004	Intentionally Not Used					N/A			
CX1005	Email from Vik Seoni to Nancy Wysenski, Robert Cobuzzi, Carolyn Kong, et al. re: Latest draft pick w/Attach: FP_Endo Strategic Opportunities_vFinal.PPT	5/30/2008	EPI001114983	EPI001114984	GX1005	JX-002			Tr. 2576:06; 2576:12; 2578:20; 2580:05
CX1006	Email from Robert Cobuzzi to Kevin Pong, Alan Butcher re: IPX66 w/Attach: IPX066_IMPAX_Partner_Confidential_032010_FINAL.PDF; ATT621896.htm: 066 Apr2010AAN poster final poster.ppt; ATT621898.htm	5/20/2010	EPI001433402	EPI001433505	GX1006; RX-068	JX-002			

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX1007	Email from Robert Cobuzzi to Ernest Kopecky, Paula Clark, Frank Diana, et al. re: IPX066 w/Attach: 066 Apr2010AAN poster final poster.ppt; IPX066_IMPAX_Partner_Confidential_032010_FINAL.PDF	5/25/2010	EPI001445208	EPI001445307	GX1007; GX1703; RX-074	JX-002		Ordered 10/23/2017	Tr. 2547:06; 2590:11; 2590:13
CX1008	Email from Mark Bradley to Robert Cobuzzi re: Project Imperial	5/27/2010	EPI001433631	EPI001433638	GX1008; RX-071	JX-002			Tr. 2585:08; 2585:12; 2585:15; 2585:23; 2588:03; 2588:04; 2589:02; 2591:09; 2591:10
CX1009	Email from Allan Miller to Robert Cobuzzi, Ellen Bernstein, David Godolphin re: Data request w/Attach: Strategic Insights.ppt	5/26/2010	EPI001433613	EPI001433618	GX1009; RX-069	JX-002			
CX1010	Intentionally Not Used					N/A			
CX1011	Email from Alan Levin to Chris Mengler, Guy Donatiello, Robert Cobuzzi re: R&D Collaboration	6/2/2010	EPI000821991	EPI000821991	GX1011; RX-043	JX-002			
CX1012	Email from Robert Cobuzzi to Michael Nestor, Chris Mengler, Alan Levin re: R&D Contract?	6/4/2010	EPI000874111	EPI000874112	GX1012	JX-002			
CX1013	Endo Document: Imperial Opportunity Evaluation Worksheet (OEW) v6	6/7/2010	EPI001306066	EPI001306082	GX1013	JX-002			
CX1014	Endo Document: Imperial Opportunity Evaluation Worksheet (OEW)_v10	6/8/2010	EPI001306083	EPI001306099	GX1014	JX-002			
CX1015	Email from Kevin Pong to Mark Bradley, Robert Cobuzzi re: GlaxoSmithKline gains rights to Impax's experimental Parkinson's disease therapy	12/17/2010	EPI001122284	EPI001122284	GX1015; GX1708; RX-058	JX-002			
CX1016	Endo Document: Development and Co-Promotion Agreement by and between Endo Pharmaceuticals Inc. and Impax Laboratories, Inc.	6/7/2010	EPI000821661	EPI000821693	GX1016	JX-002			
CX1017-CX1100	Intentionally Not Used					N/A			
CX1101	Email from Bob Barto to Tara Chapman re: documentation requested w/Attach: 20120103-Endo-NCH-DrugShortage (2).pdf	1/8/2013	EPI000033569	EPI000033578	GX1101	JX-002			Tr. 2601:05; 2601:07
CX1102	Email from Larry Romaine to Kathleen Cronshaw re: All field documents w/Attach: Endo Field Communication Letter_FAQ_ FINAL.pdf, Dear HCP Letter Endo FINAL.pdf, DearPharmacy Letter Endo Products FINAL.pdf, Dear Patient Letter Endo FINAL.pdf...	1/9/2012	EPI001065976	EPI001065991	GX1102	JX-002			
CX1103-CX1105	Intentionally Not Used					N/A			
CX1106	Email from Demir Bingol to Brian Lortie re: OPANA ER Strat. Plan w/Attach: 2010 OPANA Brand Strategic Plan-07-22-09.v7(Presentation).pptx	7/22/2009	EPI001167270	EPI001167271	GX1106; RX-061	JX-002			Tr. 2292:03; 2292:09; 2482:05; 2482:09; 2482:21; 2483:03; 2483:25
CX1107	Document: Declaration of Brian Lortie in Support of Plaintiff's Motion for Preliminary Injunction, Endo v. Actavis, Endo v. Roxane	8/5/2013	EPI001487796	EPI001488267	GX1107	JX-002		Ordered 10/20/2017	
CX1108	Email from Demir Bingol to Robert Prachar and Brian Lortie re: Revopan BoD slides w/Attach: Revopan BoD Slides-11-16-10.pptx	11/16/2010	EPI000189454	EPI000189455	GX1108	JX-002			Tr. 2451:01; 2451:02; 2451:07; 2451:22; 2453:07
CX1109	Intentionally Not Used					N/A			
CX1110	Memo from Brian Lortie to Endo Health Solutions Board of Directors re: Endo Pharmaceuticals Business Unit Performance Update	6/26/2013	EPI000003693	EPI000003696	GX1110	JX-002		Ordered 10/20/2017	
CX1111	Email from Kevin OBrien to Brian Lortie and Kevin OBrien re: Actavis Generic OER w/Attach: OXYMORPHONE ACTAVIS ANALYSOURCE.xlsx	9/24/2013	EPI000427933	EPI000427935	GX1111	JX-002			
CX1112-CX1200	Intentionally Not Used					N/A			
CX1201	FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations: Application No N020612	9/24/2014	CX1201-001	CX1201-001	GX1201; GX1229	JX-002			
CX1202	Intentionally Not Used					N/A			
CX1203	Email from Martin Black to Stephen Hash, Guy Donatiello re: Opana w/Attach: Document.pdf	2/20/2009	EPI000872253	EPI000872274	GX1203; RX-049	JX-002		Ordered 10/20/2017	
CX1204	Intentionally Not Used					N/A			
CX1205	FDA: Oxymorphone Hydrochloride, ANDA no. 079087 Approval History	9/24/2014	CX1205-001	CX1205-003	GX1205; GX1803	JX-002			
CX1206	Email from Robert Cobuzzi to Guy Donatiello, Alan Levin, Roberto Cuca, et al. re: IPX066 w/Attach: DATA LIST.docd; ATT808802.htm	5/22/2010	EPI001588123	EPI001588132	GX1206	JX-002			
CX1207	Intentionally Not Used					N/A			

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX1208	Email from Robert Cobuzzi to Dave Holveck, Alan Levin, Caroline Manogue, et al. re: Imperial OEW w/Attach: 052810 Imperial OEW v5.docx	6/1/2010	EPI001448405	EPI001448421	GX1208: GX1010; GX1416	JX-002			Tr. 2593:06; 2593:08; 2594:06; 2594:15; 2595:12

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX1312-CX1313	Intentionally Not Used					N/A			
CX1314	Email from Roberto Cuca to Alan Levin re: <no subject>	6/1/2010	EPI000873999	EPI000873999	GX1314	JX-002			Tr. 659:11
CX1315	Intentionally Not Used					N/A			
CX1316	Email from Julie McHugh to Alan Levin, Denise Craig, Nancy Olson re: Two Documents for EPC Today at 4:30 w/Attach: FW: Approval Requested - Oxymorphone ER Pricing; FW: Approval Requested - Oxymorphone ER Pricing								

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX1818	Email from Guy Donatiello to Edward Sweeney re: <no subject> w/Attach: Impax Laboratories, Inc.-Development&Co-PromotionAgmtJun10.pdf; Emailing: Impax Laboratories, Inc.-Development&Co-PromotionAgmtJun10.pdf	6/24/2010	EPI000874308	EPI000874343	GX1818	JX-002			
CX1819	Email from Steve Mollichella to Robert Cooper, Guy Donatiello, Meg Snowden, et al. re: Upfront pa								

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX2566	Email from Andy Gesek to Alan Levin, Roberto Cuca, Jack Boyle re: 2013 Apr LBE AG Version.pptx w/Attach: 2013 Apr LBE AG Version.pptx	4/17/2013	EPI000342149	EPI000342150		JX-002			
CX2567	Email from Alan Levin to Roberto Cuca re: Impax - Endo w/Attach: Redline - Impax-Endo Settlement and License Agreement.pdf; Draft Impax - Endo SettlementAgreement (Opana) [Endo Markup] (3).DOC	6/7/2010	EPI001588988	EPI001588937		JX-002			
CX2568-CX2569	Intentionally Not Used					N/A			
CX2570	Document: Impax Strategy for Opana ER	6/27/2012	EPI000003426	EPI000003430		JX-002			
CX2571	Email from Debbie Travers to Kristin Livingston, Beth Aranilla, Tracy Wilson, et al. re: Slides for Opana R&D Project Review w/Attach: Opana Project Review June 08.ppt	6/4/2008	EPI000091510	EPI000091511		JX-002			
CX2572	Email from Linda Kitlinkski to ClinEd re: QBR DRAFT Slides - Opana Brad w/Attach: OPANA Brand QBR-01-30-09.v6.ppt	2/10/2009	EPI000210720	EPI000210721		JX-002		Ordered 10/20/2017	
CX2573	Presentation: EN3288 Commercial Update, Demir Bingol	2/24/2010	EPI000290472	EPI000290472		JX-002			Tr. 1297:13; 1297:14; 1297:24; 1298:01; 1298:08; 1298:15
CX2574	Intentionally Not Used					N/A			
CX2575	Email from Demir Bingol to Tara Chapman, Bob Barto, Diana Frank, and William Fiske re: EN3288 Review-05-5-10 TC.pptx w/Attach: EN3288 Review-05-05-10.v2.pptx	5/6/2010	EPI000631980	EPI000631981		JX-002			
CX2576	Email from Demir Bingol to Kayla Kelnhofer re: No Subject	2/11/2010	EPI000914419	EPI000914421		JX-002			
CX2577	Email from Doug Azzalina to Javier Avalos, Robert Candea, Steven Cooper, and Demir Bingol re: oxymorphone ER AG data req62.2031 88.eesC BT/TD <</MCID 70 >>BDC 0 6.52 -5.52 0 255.96 238.0259 Tm(2/248810)TjEMC /TD <</MCID 51 >>BDC 47791 0 Td(EPI000914419)TjE5042/TD <</MCID 72 >>BDC 148933 0 Td(EPI000914421)TjE5043/TD <</MCID 51 >>BDC 47989								
	10/20/2017								

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX2608	Plaintiff-Appellant's Reply In Support of Motion for an Injunction Pending Trial, Endo Pharmaceuticals Inc. v. Actavis, Inc. and Actavis South Atlantic, LLC	9/27/2013	EPI001486613	EPI001487275		JX-002			
CX2609	Decalaration of Henry G. Grabowski, Ph. D. In Support of Plaintiff's Motion for Preliminary Injunction, Endo Pharmaceuticals Inc v. Actavis Inc. and Actavis South Atlantic LLC, Endo Pharmaceuticals Inc v. Roxane Laboratories, Inc.	8/5/2013	EPI001488515	EPI001488566		JX-002		Ordered 10/20/2017	
CX2610	Email from Christine Crooks to Demir Bingol re: Revopan Playbook--PLEASE REVIEW MONDAY w/Attach: 2352_abbnhl_revopan_plybkv_lo5.pptx	12/11/2010	EPI000319915	EPI000319916		JX-002			Tr. 1269:18; 1269:20; 1269:22; 1311:20
CX2611	Email from David Macera to Alan Levin and Karen Adler re: 10 Yr Plan w/Attach: 10 yr Outlook v7 Q3 2012 Case.pdf, 10 Yr Outlook v7 Q3 2013 Case.pdf, 10 yr Outlook v7 Base Case.pdf, 10 yr Outlook with Kansas v7.xlsx	3/21/2011	EPI001901990	EPI001902036		JX-002			
CX2612	Intentionally Not Used					N/A			
CX2613	Email from Todd Engle to Shawn Fatholahi re: Actavis' Generic Opana ER Receives FDA Approval w/Attach: Graphs 07_17_13.xls	8/21/2013	IMPAX-OPANA-CID00007908	IMPAX-OPANA-CID00007914	RX-343	JX-002			
CX2614-CX2615	Intentionally Not Used					N/A			
CX2616	Email from Guy Donatiello to Chris Mengler, Meg Snowden, Alan Levin, et al. re: Highly Confidential - Rule 408 Settlement Communication	5/26/2010	IMPAX-OPANA-CID00005625	IMPAX-OPANA-CID00005626	RX-311	JX-002			
CX2617-CX2624	Intentionally Not Used					N/A			
CX2625	Email from Michael Nestor to David Paterson re: IPX066	5/22/2010	IMPAX-OPANA-CID00006708	IMPAX-OPANA-CID00006711		JX-002			Tr. 3012:06; 3012:07; 3012:09; 3013:16; 3014:25
CX2626	Impax Document: Settlement and License Agreement	7/6/2010	Impax_Opana_PartIII_0000147	Impax_Opana_PartIII_0000172	RX-364	JX-002			Tr. 1926:13
CX2627	Impax Presentation: Board of Directors Meeting February 2010	2/00/2010	Impax_Opana_PartIII_0002024	Impax_Opana_PartIII_0002054	RX-150	JX-002		Ordered 10/23/2017	
CX2628	Impax Presentation: Board of Directors Meeting November 2009	11/11/2009	Impax_Opana_PartIII_0002055	Impax_Opana_PartIII_0002090	RX-151	JX-002		Ordered 10/23/2017	
CX2629	Impax Presentation: Board of Directors Meeting August 2010	8/00/2010	Impax_Opana_PartIII_0002152	Impax_Opana_PartIII_0002193		JX-002			
CX2630	Email from David Paterson to Robert Cobuzzi, Michael Nestor, Chris Mengler, et al. re: IPX066	5/21/2010	IMPAX-OPANA-CID00001683	IMPAX-OPANA-CID00001685		JX-002			
CX2631-CX2634	Intentionally Not Used					N/A			
CX2635	Email from Kevin Sica to Ted Smolenski re: Zorn Model Oxymorphone 03 12 10.xls w/Attach: Zorn Model Oxymorphone 03 12 10.xls	3/12/2010	IMPAX-OPANA-CID00007071	IMPAX-OPANA-CID00007072		JX-002			
CX2636	Email from Todd Engler to Chris Mengler re: Zorn Model Oxymorphone 03 11 10.xls w/Attach Zorn Model Ox_								

PUBLIC

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As				

IN THE [redacted]
DOC[redacted]

COMPLAINT CO[redacted]

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX2724	Email from Demir Bingol r4.783 0 Td(Date)TjEMC /Dave Holveck, B								

PUBLIC

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date							

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX2826	Email from Kevin Sica to Chris Mengler, Ted Smolenski, Todd Engle re: 5 Year Forecast w/Attach: 5-year forecast 2010-02-17.xls_UPSIDE	2/17/2010	IMPAX-OPANA-CID00007117	IMPAX-OPANA-CID00007118		JX-002			
CX2827	Intentionally Not Used					N/A			
CX2828	Email from Joyce De Los Reyes to Joe Camargo, Kevin Sica, Chuck Hildenbrand, et al. re: Generic new product launch projection 2010-04-05.xls w/Attach: Generic new product launch projection 2010-04-05.xls	4/5/2010	IMPAX-OPANA-CID00014245	IMPAX-OPANA-CID00014246	RX-369	JX-002			
CX2829	Email from Kevin Sica to Denis Paquette, Tony Bright, Joe Camargo, et al. re: May Forecast Submission w/Attach: Forecast Change From Previous Forecast 0510.xls	5/7/2010	Impax_Opana_PartIII_0022454	Impax_Opana_PartIII_0022455		JX-002			
CX2830	Email from Ted Smolenski to Chris Mengler, Kevin Sica, Todd Engle re: 5-year forecast 2010-May Update 2010--05-14v5.xls w/Attach: 5-year forecast 2010-May Update 2010--05-14v5.xls_UPSIDE	5/15/2010	IMPAX-OPANA-CID00007077	IMPAX-OPANA-CID00007078		JX-002			
CX2831	Email from Ted Smolenski to Art Koch re: 5-year forecast 2010-May Update 2010--05-21--UPSIDE.xls w/Attach: 5-year forecast 2010-May Update 2010--05-21--UPSIDE.xls	5/21/2010	IMPAX-OPANA-CID00006578	IMPAX-OPANA-CID00006579		JX-002			
CX2832-CX2837	Intentionally Not Used					N/A			
CX2838	Email from Kevin Sica to Denis Paquette, Tony Bright, Joe Camargo, et al. re: June Forecast Submission w/Attach: Forecast Change From Previous Forecast 0610.xls	6/7/2010	Impax_Opana_PartIII_0013045	Impax_Opana_PartIII_0013046		JX-002			
CX2839-CX2841	Intentionally Not Used					N/A			
CX2842	Email from Kevin Sica to Denis Paquette, Tony Bright, Joe Camargo, et al. re: July Forecast Submission w/Attach: Forecast Change From Previous Forecast 0710.xls	7/12/2010	Impax_Opana_PartIII_0030783	Impax_Opana_PartIII_0030785		JX-002			
CX2843-CX2844	Intentionally Not Used					N/A			
CX2845	Email from Meg Snowden to Guy Donatiello, Andy Gesek, Roberto Cuca, Carrie Cooper, et al. re: steering committee	12/20/2010	IMPAX-OPANA-CID00006165	IMPAX-OPANA-CID00006166		JX-002			
CX2846-CX2850	Intentionally Not Used					N/A			
CX2851	Impax Document: Consulting Agreement between Impax Laboratories, Inc. and TCS Consulting Group,								

L76 88.68 6C/TD <</MCID 85 >>BDC 67.065 0 Td(7/12/20104/44Tm(N/A)TjEMC /TD <</MCID 62 >>82.48 353.6518 Tm(p)1ro Bratories,18 /HyphenSpan <</MCID 80 >>BDC (-)TjEMCp)1ro Bratories,18 /HyphenSpQBT0 5.52 -5.52 0 282.48 365.6217 Tm(O3 Tm.6196 Tm(0030783)TjET

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX2869	Email from Joe Camargo to Tamara Alegria re: Oxymorphone	1/11/2010	Impax_Opana_PartIII_0017165	Impax_Opana_PartIII					

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX2902	Email from Willi Huang to Joe Camargo, Chuck Hildenbrand, Kangwen Lin, et al. re: Oxymorphone	5/5/2011	Impax_Opana_PartIII_0026107	Impax_Opana_PartIII_0026108		JX-002			
CX2903	Intentionally Not Used					N/A			
CX2904	Email from Joe Camargo to Chuck Hildenbrand, Tony Bright, Jim Larrowe, et al. re: June Plan	5/25/2010	Impax_Opana_PartIII_0030026	Impax_Opana_PartIII_0030026	RX-187	JX-002			Tr. 1017:08
CX2905	Email from Joe Camargo to Chuck Hildenbrand re: Monthly Report w/Attach: Monthly Report, 5-10.doc	6/11/2010	Impax_Opana_PartIII_0030763	Impax_Opana_PartIII_0030765		JX-002			Tr. 989:14; 990:05, 10; 1022:25; 1023:07
CX2906	Email from Todd Engle to Chris Mengler, Larry Hsu, Richard Ting, et al. re: Agenda and hand out for the Quarterly Launch Planning Meeting today	11/24/2009	Impax_Opana_PartIII_0044720	Impax_Opana_PartIII_0044723		JX-002			
CX2907	Intentionally Not Used					N/A			
CX2908	Email from Kangwen Lin to Andrew Fox, Art Koch, Chris Mengler, et al. re: Generic meeting update - operation activities for 6/15 meeting w/Attach: OA for Generic meeting June 15.doc	6/15/2010	Impax_Opana_PartIII_0046747	Impax_Opana_PartIII_0046749		JX-002			
CX2909	Intentionally Not Used					N/A			
CX2910	Email from Joe Camargo to Chris Mengler re: Alternate Sourcing Projects	4/9/2009	Impax_Opana_PartIII_0049209	Impax_Opana_PartIII_0049210		JX-002			
CX2911-CX2913	Intentionally Not Used					N/A			
CX2914	Email from Joe Camargo to Andrew Fox, Art Koch, Bob Friedel, et al. re: Updated Checklist w/Attach: Product Launch Checklist.xls	6/8/2010	Impax_Opana_PartIII_0077849	Impax_Opana_PartIII_0077850	RX-226	JX-002			
CX2915	Email from Joe Camargo to Andrew Fox, Art Koch, Chuck Hildenbrand, et al. re: Updated Checklist w/Attach: Product Launch Checklist.xls	10/27/2009	Impax_Opana_PartIII_0079132	Impax_Opana_PartIII_0079133		JX-002			
CX2915A	Email from Joe Camargo to Andrew Fox, Art Koch, Chuck Hildenbrand, et al. re: Updated Checklist w/Attach: Product Launch Checklist.xls	10/27/2009	Impax_Opana_PartIII_0079132	Impax_Opana_PartIII_0079133		JX-002			
CX2916	Email from John Anthony to Todd Engle, Chris Mengler, Mark Shaw re: Oxymorphone w/Attach: 1936_001.pdf; Oxymorphone Forecast Detail 01 11 10 R2.xls	1/12/2010	Impax_Opana_PartIII_0019522	Impax_Opana_PartIII_0019537		JX-002			
CX2917	Letter from John Anthony to Christine Sannerud, DEA re: Oxymorphone Procurement Quota Year 2010	1/18/2010	Impax_Opana_PartIII_0081690	Impax_Opana_PartIII_0081692		JX-002			
CX2918	Letter from John Anthony to Christine Sannerud, DEA re: Oxymorphone Procurement Quota Year 2010	4/15/2010	Impax_Opana_PartIII_0081693	Impax_Opana_PartIII_0081695		JX-002			
CX2919	Impax Document: Minutes of the Meeting of the Board of Directors of Impax Laboratories, Inc.	8/17/2010							

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX2933	Meeting Scheduler re: Co-Promote Teleconference with Attendees: Brian Lortie, Alan Levin, Robert Cobuzzi, Meg Snowden, et al.	6/7/2010	IMPAX-OPANA-CID00006143	IMPAX-OPANA-CID00006143	RX-326	JX-002			
CX2934	Intentionally Not Used					N/A			
CX2935	Email from Justin Watkins to Alison Freeman Gleason, Meg Snowden, Alan Levin, et al. re: Co-Promote Revisions w/Attach: #710157v9_BE01_ - Impax - Co-Promotion Agreement.DOC; et al.	6/7/2010	IMPAX-OPANA-CID00006853	IMPAX-OPANA-CID00006918		JX-002			
CX2936	Email from Meg Snowden to Joyce De Los Reyes re: Generic new product launch projection 2010-06-08 MS.xls	6/14/2010	IMPAX-OPANA-CID00020529	IMPAX-OPANA-CID00020530		JX-002			
CX2937	Intentionally Not Used					N/A			
CX2938	Email from Meg Snowden to Tim Scott and Mark Schlossberg re: EXTERNAL:RE: Impax License Agreement	4/21/2016	IMPAX-ENDO-DNJ0001564	IMPAX-ENDO-DNJ0001568		JX-002			
CX2939	Email from Meg Snowden to Fred Wilkinson, Douglas Boothe, and Mark Schlossberg re: Endo v. Impax	11/3/2016	IMPAX-ENDO-DNJ0005272	IMPAX-ENDO-DNJ0005275		JX-002			
CX2940-CX2941	Intentionally Not Used					N/A			
CX2942	Email from Guy Donatiello to Meg Snowden re: Impax License Agreement	10/1/2015	EPI002195693	EPI002195695		JX-002			
CX2943	Email from Guy Donatiello to Meg Snowden, George Gordon, Jennifer Dubas, et al. re: EXTERNAL: Impax License Agreement	4/19/2016	EPI002195706	EPI002195709		JX-002			
CX2944	Email from Guy Donatiello to Bob Rhoad, Martin Black, Matthew Maletta, et al. re: Letter to Mr. Chris Mengler and Ms. Margaret Snowden, Impax Laboratories, Inc.	10/31/2016	EPI002195723	EPI002195725		JX-002			Tr. 2905:01; 2905:05
CX2945-CX2946	Intentionally Not Used					N/A			
CX2947	Impax Presentation: Company Goal and Strategy November 17, 2009	11/17/2009	Impax_Opana_PartIII_0003904	Impax_Opana_PartIII_0003916		JX-002			
CX2948	Email from Suneel Gupta to Michael Nestor re: Endo contact person	6/3/2010	IMPAX-OPANA-CID00001599	IMPAX-OPANA-CID00001599	RX-269	JX-002			
CX2949	Email from Robert Cobuzzi to Michael Nestor, Chris Mengler, Alan Levin re: R&D Contact?	6/4/2010	IMPAX-OPANA-CID00001611	IMPAX-OPANA-CID00001612	RX-273	JX-002			
CX2950-CX2951	Intentionally Not Used					N/A			
CX2952	Email from Laura Zhu to Michael Nestor re: IPX066	5/21/2010	IMPAX-OPANA-CID00006714	IMPAX-OPANA-CID00006716		JX-002			
CX2953	Email from Bryan Reasons to Michael Nestor, Suneel Gupta re: Impax/Endo Development and Co-Promotion Agreement Milestones w/Attach: image001.png; image002.png	4/16/2013	IMPAX-OPANA-CID00007983	IMPAX-OPANA-CID00007987	RX-344	JX-002			
CX2954	Email from Suneel Gupta to Steve Mollichella, Meg Snowden, Michael Nestor re: Co-Promote Revisions	7/1/2010	IMPAX-OPANA-CID00011919	IMPAX-OPANA-CID00011923	RX-358	JX-002			
CX2955	Email from Michael Nestor to Suneel Gupta re: BoD slides w/Attach: BOD draft ver3.ppt	8/1/2010	IMPAX-OPANA-CID00012655	IMPAX-OPANA-CID00012699	RX-368	JX-002		Ordered 10/23/2017	
CX2956	Email from Michael Nestor to Brandon Smith re: Slide format w/Attach: BOD 07092013.ppt	7/5/2013	IMPAX-OPANA-CID00016072	IMPAX-OPANA-CID00016091	RX-370	JX-002		Ordered 10/23/2017	
CX2957	Email from Mark Donohue to Michael Nestor re: Call w/Attach: Impax Key Topic Messaging Points - Sept 28 2012.docx	9/27/2012	IMPAX-OPANA-CID00018692	IMPAX-OPANA-CID00018703		JX-002			
CX2958	Email from Larry Hsu to Bryan Reasons, Carole Ben-Maimon, Michael Nestor, et al. re: What has been disclosed	7/5/2012	IMPAX-OPANA-CID00019206	IMPAX-OPANA-CID00019208		JX-002			
CX2959	Intentionally Not Used					N/A			
CX2960	Email from Chris Mengler to Meg Snowden, Art Koch, Larry Hsu, et al. re: <no subject>	6/3/2010	IMPAX-OPANA-CID00019454	IMPAX-OPANA-CID00019454		JX-002			
CX2961	Email from Larry Hsu to Art Koch, Meg Snowden, Michael Nestor, et al. re: Status	6/5/2010	IMPAX-OPANA-CID00019476	IMPAX-OPANA-CID00019476		JX-002			
CX2962	Email from Meg Snowden to Michael Nestor, Shawn Fatholahi, Suneel Gupta, et al. re: R&D Collaboration	6/6/2010	IMPAX-OPANA-CID00021838	IMPAX-OPANA-CID00021839	RX-569	JX-002			
CX2963	Email from Michael Nestor to Meg Snowden, Art Koch, Larry Hsu, et al. re: Info requested by Endo on successor to IPX-066	6/4/2010	IMPAX-OPANA-CID00022261	IMPAX-OPANA-CID00022261		JX-002			
CX2964	Email from Jennifer Saionz to Alan Levin, Guy Donatiello, Martin Black, et al. re: Impax - Endo w/Attach: Impax inserts_(PAU 81_3993075_1) .DOC	6/6/2010	IMPAX-OPANA-CID00001416	IMPAX-OPANA-CID00001438	RX-267	JX-002			

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX2965	Email from Justin Watkins to Alison Freeman Gleason, Meg Snowden, Michael Nestor, et al. re: Co-Promotion Agreement - Revised Draft w/Attach: #710157v7_BE01_ - Impax - Co-Promotion Ag								

COMPLAINT COUNSEL'S EXHIBIT INDEX

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX3049	Endo Press Release: Endo Health Solutions Responds to FDA 's Denial of OPANA® ER Citizen Petition and the Potential Approval of Additional Non-Abuse Deterrent Formulations of Generic Oxymorphone	5/10/2013	CX3049-001	CX3049-003		JX-002			
CX3050	Intentionally Not Used					N/A			
CX3051	Endo Presentation: Ratings Agency Presentation	7/19/2013	EPI002160028	EPI002160028		JX-002			
CX3052	Intentionally Not Used					N/A			
CX3053	Email from Ray Smith to Joe Camargo, Chuck Hildenbrand, and Rfrom RTq111.72248.68 6.12 34.921	5036 nBT0 5.52	-5.52 0 116.76 501.07350126g						

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX3089	Email from Joyce De Los Reyes to Joe Camargo, Charles Hildenbrand, Pete Valko, et al. re: Generic new product launch projection 081208.xls	8/12/2008	IMPAX-OPANA-CID00012345	IMPAX-OPANA-CID00012346		JX-002			
CX3090									

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX3127-CX3128	Intentionally Not Used					N/A			
CX3129	Endo Spreadsheet: Endo Contribution Margin Report - Period	6/11/2014	EPI000731506	EPI000731506		JX-002			
CX3130	Email from Roberto Cuca to Alan Levin, Darnell Turner, and David Macera re: Per share price impact of generic Opana ER launch	3/15/2010	EPI002159607	EPI001588193	RX-130	JX-002			
CX3131	Email from Alan Levin to Roberto Cuca, Karen Adler, Mark Bradley, and Denise Craig re: Impax and Sandoz Litigations Settled w/Attach: Sandoz June 2010 FINAL Joint-1.doc	6/8/2010	EPI002200039	EPI002200047		JX-002			
CX3132	Email from Alan Levin to Robert Cobuzzi re: IPX066	5/22/2010	EPI002201680	EPI002201682		JX-002			
CX3133	Email from Alan Levin to Blaine Davis re: Penwest Royalties	6/7/2010	EPI002201727	EPI002201728		JX-002			
CX3134	Endo Document: Key Messages	6/4/2010	EPI002209609	EPI002209611		JX-002			
CX3135	Endo Document: Minutes of a Special Meeting of the Board of Directors of Endo Pharmaceuticals Holdings Inc.	5/27/2010	EPI002219841	EPI002219842		JX-002			
CX3136	Email from Caroline Manogue to Jonathan Neely, Alan Levin, Sean Lannon, et al. re: Jefferies Investor Slides v3.pptx w/Attach: Jefferies Investor Slidesv3.pptx, ENDP Jefferies Global Life Sciences Script v3.docx	6/9/2010	EPI002221135	EPI002221149		JX-002			
CX3137-CX3139	Intentionally Not Used					N/A			
CX3140	Impax Presentation: Impax Generic Business Board of Directors Meeting December 11, 2014	12/11/2014	Impax_Opana_PartIII_0003069	Impax_Opana_PartIII_0003109		JX-002		Ordered 10/23/2017	
CX3141	Intentionally Not Used					N/A			
CX3142	Email from Sammy Bhardwaj to Tamara Alegria, Joe Camargo and John Anthony re: Attached Image	3/8/2010	Impax_Opana_PartIII_0015359						

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX3160	Document: Endo Pharmaceuticals Holdings Inc. SEC Form 10-K 2009	2/26/2010	CX3160-001	CX3160-228		JX-002			
CX3161	Intentionally Not Used					N/A			
CX3162	Document: Impax White Paper to FTC	2/16/2015	CX3162-001	CX3162-045		JX-002			
CX3163	Document: Answer of Respondent Impax Laboratories Inc. to the Federal Trade Commission's Administrative Complaint	2/7/2017	CX3163-001	CX3163-024		JX-002			
CX3164	Document: Respondent Impax Laboratories, Inc.'s Objections and Responses to Complaint Counsel's Requests for Admission	8/3/2017	CX3164-001	CX3164-022		JX-002			
CX3165	Email from David Paterson to Suneel Gupta re: IPX203	11/17/2014	Impax_Opana_PartIII_0059855	Impax_Opana_PartIII_0059855		JX-002			
CX3166	Impax Presentation: Impax Pharmaceutical R&D	1/24/2013	IMPAX-OPANA-CID00019616	IMPAX-OPANA-CID00019694		JX-002		Ordered 10/23/2017	
CX3167	Impax Presentation: Brand R&D Presentation	8/11/2010	IMPAX-OPANA-CID00019989	IMPAX-OPANA-CID00020051		JX-002		Ordered 10/23/2017	
CX3168	Email from Richard Reeve to Kevin Pong, Mark Bradley, Debbie Travers, et al. re: Project Biloxi: Revisions to the OEW w/Attach: 041211 Biloxi OEW v13 RR.docx, Microsoft_Powerpoint_Slide1.sldx	4/13/2011	EPI000161793	EPI000161829		JX-002			
CX3169	Email from Demir Bingol to Brian Lortie and Steven Cowan re: EOC action item re: Opane ER / 3288 supply chain	2/8/2011	EPI000189554	EPI000189556		JX-002			
CX3170	Email from Sam Rasty to Demir Bingol re: Opana A&P cost question w/Attach: OEW for Project Nevada - Nekfar-118 license 16May08 + market opp.doc,								

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX3182	Email from Guy Donatiello to Ginola Johnson re: Agreements w/Attach: Sandoz - Endo Settlement Agreement EXECUTION VERSION.pdf; Impax - Endo Settlement Agreement_Opana_[Execution Version].pdf; Impax-Endo Co-Promotion Agreement.pdf	6/21/2010	EPI000828479	EPI000828555		JX-002			
CX3183	Email from Art Koch to Alan Levin, Meg Snowden, Guy Donatiello, et al. re: Gross Margin	6/7/2010	EPI000874092	EPI000874092		JX-002			
CX3184	Email from Brian Lortie to Julie McHugh re: Update	6/7/2010	EPI001170646	EPI001170647		JX-002			
CX3185	Email from Todd Engle to Joe Camargo, Meg Snowden re: Launch Planning Input w/Attach: QLPM 051810 Draft.doc	5/18/2010	Impax_Opana_PartIII_0077527	Impax_Opana_PartIII_0077571		JX-002			
CX3186	Email from Meg Snowden to Guy Donatiello re: Signature pages	6/8/2010	IMPAX-OPANA-CID00002220	IMPAX-OPANA-CID00002220		JX-002			
CX3187	Email from Larry Hsu to Ted Smolenski, Art Koch re: opana ER	1/8/2011	IMPAX-OPANA-CID00003557	IMPAX-OPANA-CID00003558	RX-293	JX-002			
CX3188	Endo Press Release: Endo Pharmaceuticals Reports Strong Third Quarter 2010 Financial Results; Reaffirms 2010 Financial Guidance and Provides Financial Guidance for 2011	11/1/2010	CX3188-001	CX3188-018		JX-002			
CX3189	Endo Press Release: Endo Pharmaceuticals Agrees to Acquire Penwest Pharmaceuticals and Submits NDA for New Formulation of Long-Acting Oxy								

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX3232	Email from Larry Kloss to Art Koch re: 5-year forecast 2010-May Update 201--05-14v5.xls w/Attach: 5-year forecast 2010-May Update 201--05-14v5.xls	5/15/2010	IMPAX-OPANA-CID00007080	IMPAX-OPANA-CID00007081		JX-002			
CX3233	Intentionally Not Used					N/A			
CX3234	Compl., Endo Pharm. Inc. v. Par Pharm. Co., No. 1:12-cv-09261-UA (S.D.N.Y. Dec. 19, 2012)	12/19/2012	CX3234-001	CX3234-003		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3235	Dkt. No. 209, Endo Pharm. Inc. v. Actavis LLC, No. 14-cv-01381-RGA (D. Del. Apr. 7, 2017)	4/7/2017	CX3235-001	CX3235-001		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3236	Intentionally Not Used					N/A			
CX3237	Endo Pharm. Inc. v. Teva Pharm. USA, Inc., No. 15-2021 (Fed. Cir. appeal docketed Sept. 15, 2015)	9/15/2015	CX3237-001	CX3237-001		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3238-CX3239	Intentionally Not Used					N/A			
CX3240	Endo Press Release: Endo Announces Commercial Availability of Opana® ER (oxymorphone HCl)								

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX3273	Document: Declaration of Demir Bingol, Civil Action Nos. 09-cv-831 (KSH) (PS), 09-cv-832 (KSH) (PS), 09-cv-833 (KSH) (PS)	5/21/2010	CX3273-001	CX3273-010	RX-486	JX-002			Tr. 1280:22; 1280:24; 1281:01; 1281:02; 1281:14; 1281:21; 1282:02; 1282:05; 1282:15; 1283:08; 1286:18; 1287:23; 1287:25; 1288:13; 1292:23; 1315:23
CX3274	Email from Chris Mengler to Chuck Hildenbrand, Art Koch, Meg Snowden, et al. re: Oxymorphone ER Tablets Tentatively Approved Today!!	5/13/2010	Impax_Opana_PartIII_0068875	Impax_Opana_PartIII_0068876		JX-002			
CX3275	Document: Contract Settlement Agreement [Execution Version]	8/5/2017	Impax_Opana_PartIII_0081712	Impax_Opana_PartIII_0081742		JX-002		Ordered 10/23/2017	Tr. 2724:08; 2729:10
CX3276	Document: First Amendment to 2010 Settlement and License Agreement [Execution Version]	8/5/2017	Impax_Opana_PartIII_0081743	Impax_Opana_PartIII_0081763		JX-002			

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX3310	Email from Anna Fabish to Nick Leefer, Ted Hassi, Michael Antalics, et al. re: Docket 9373 - Forecast and Board of Director Documents in Impax"s Productions w/Attach: 7202017_Letter_to_Complaint_Counsel_ re_Board_Documents_and_Forecasts_.pdf	7/21/2017	CX3310-001	CX3310-010		JX-002			
CX3311	Email from William Hicks to Jamie Towey, Paula Blizzard re: Civil Investigative Demand to Impax Laboratories, Inc. (FTC File No. 141004) w/Attach: March 27, 2014 Ltr. to J. Towey.PDF	3/27/2014	CX3311-001	CX3311-006		JX-002			
CX3312	Letter from Anna Fabish to Nick Leefer re: In re Impax Laboratories, Inc., Dkt. No. 9373	5/11/2017	CX3312-001	CX3312-010		JX-002		Ordered 10/23/2017	
CX3313	Document: Q4 2009 Impax Laboratories Earnings Conference Call - Final	2/25/2010	CX3313-001	CX3313-015		JX-002			
CX3314	Letter from Joshua Davis to J. Maren Schmidt re: FTC File No. 1410004 / Endo Pharmaceuticals Inc.	6/16/2014	CX3314-001	CX3314-008		JX-002			
CX3315	Intentionally Not Used					N/A			
CX3316	Email from J. Maren Schmidt to Barbara Wootton, Jamie Towey, Eric Sprague, et al. re: Endo Pharmaceuticals Inc.	4/20/2015	CX3316-001	CX3316-005		JX-002			
CX3317	Actavis Document: ActionSTAT Additional Pack Size Availability for Oxymorphone Hydrochloride Extended-Release	1/2/2014	Actavis_FTC_Opana_000377	Actavis_FTC_Opana_000377		JX-002			
CX3318	Endo Spreadsheet: 2008-2013 ER 553-70	6/11/2014	EPI000731503	EPI000731503		JX-002		Ordered 10/20/2017	
CX3319	Endo Spreadsheet: 2008-2013 ER 571-70	6/11/2014	EPI000731504	EPI000731504		JX-002		Ordered 10/20/2017	
CX3320	Endo Spreadsheet: 2008-2013 ER 617-70	6/11/2014	EPI000731505	EPI000731505		JX-002		Ordered 10/20/2017	
CX3321	Endo Spreadsheet: 2008-2013 ER 674-70	6/11/2014	EPI000731507	EPI000731507		JX-002		Ordered 10/20/2017	
CX3322	Endo Spreadsheet: 2008-2013 ER 693-70	6/11/2014	EPI000731508	EPI000731508		JX-002		Ordered 10/20/2017	
CX3323	Endo Spreadsheet: 2008-2013 ER 907-70	6/11/2014	EPI000731509	EPI000731509		JX-002		Ordered 10/20/2017	
CX3324	Endo Spreadsheet: 2008-2013 ER 907-75	6/11/2014	EPI000731510	EPI000731510		JX-002			
CX3325	Endo Spreadsheet: 2012-2013 TRF ALL	6/11/2014	EPI000731512	EPI000731512		JX-002		Ordered 10/20/2017	
CX3326	Endo Sp								

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX3338	Email from Kevin Pong to Stephen Bai, Paula Clark, Frank Diana, et al. re: Project Imperial DD Reports w/Attach: Project Imperial_Regulatory DD Report_Clark.docx; Project Imperial_ CDMA DDReport_Kopecky.docx; Project Imperial_Clin Pharm DD Report_Bai.doc	6/3/2010	EPI002156237	EPI002156256		JX-002			
CX3339	Email from Ivan Gergel to Stephen Bai, Frank Diana, Sandeep Gupta re: Information Requested	6/5/2010	EPI002159879	EPI002159881		JX-002			Tr. 2603:18; 2603:20; 2603:23
CX3340	Email from Karen Adler to Edward Sweeney re: You are not alone	6/5/2010	EPI002161112	EPI002161112		JX-002			
CX3341	Email from Mark Bradley to Julie McHugh, Lori Tierney re: Data request	6/7/2010	EPI002161155	EPI002161163		JX-002			
CX3342	Impax Document: Co-Promotion Agreement dated as								

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX3361	Case 2:16-cv-02526-JLL-JAD: Opinion	10/25/2016	CX3361-001	CX3361-014		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3362	Case 2:16-cv-02526-JLL-JAD: Order	10/25/2016	CX3362-001	CX3362-001		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3363	Case 2:16-cv-02526-JLL-JAD: Joint Discovery Plan	1/30/2017	CX3363-001	CX3363-011		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3364	Case 2:16-cv-02526-JLL-JAD: Pretrial Scheduling Order	2/6/2017	CX3364-001	CX3364-004		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3365	Case 2:16-cv-02526-JLL-JAD: Letter from Brian Goldberg to Judge Dickson re: Joint Proposed Revised Scheduling Order	5/4/2017	CX3365-001	CX3365-039		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3366	Case 2:16-cv-02526-JLL-JAD: Discovery Confidentiality Order	5/5/2017	CX3366-001	CX3366-029		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3367	Case 2:16-cv-02526-JLL-JAD: Revised Scheduling Order	5/5/2017	CX3367-001	CX3367-001		JX-002	Admitted solely for nonhearsay purposes, i.e., not for the truth of any matter asserted		
CX3368	Case 2:16-cv-02526-JLL-JAD: Joint Letter to Judge Dickson re: Discover								

COMPLAINT COUNSEL'S EXHIBIT INDEX

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX3456	Case 09-cv-831, 832, 833: Declaration of John S. Russell, M.S.	5/21/2010	EPI002496955	EPI002496985		JX-002			
CX3457-CX3999	Intentionally Not Used					N/A			
CX4000	Excerpt of IH Transcript: Paul Bisaro (Actavis)	11/20/2014	CX4000-001	CX4000-051		JX-002			
CX4001	IH Transcript: Arthur A. Koch, Jr (Impax)	10/27/2014	CX4001-001	CX4001-072		JX-002			
CX4002	IH Transcript: Theodore Smolenski (Impax)	9/30/2014	CX4002-001	CX4002-088		JX-002			Tr. 1658:09
CX4003	IH Transcript: Margaret Snowden (Impax)	10/15/2014	CX4003-001	CX4003-080 g					

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility	Purpose/Notes	*In Camera*	Trial Transcript Citation
CX5004									

COMPLAINT COUNSEL'S EXHIBIT INDEX

Exhibit No.	Description	Date	BegBates	EndBates	Also Referenced As	Admissibility			

Notice of Electronic Service

I hereby certify that on January 04, 2018, I filed an electronic copy of the foregoing Complaint Counsel's Exhibit List, with:

D. Michael Chappell
Chief Administrative Law Judge
600 Pennsylvania Ave., NW
Suite 110
Washington, DC, 20580

Donald Clark
600 Pennsylvania Ave., NW
Suite 172
Washington, DC, 20580

I hereby certify that on January 04, 2018, I served via E-Service an electronic copy of the foregoing Complaint Counsel's Exhibit List, upon:

Bradley Albert
Attorney
Federal Trade Commission
balbert@ftc.gov
Complaint

Daniel Butrymowicz
Attorney
Federal Trade Commission
dbutrymowicz@ftc.gov
Complaint

Nicholas Leefer
Attorney
Federal Trade Commission
nleefer@ftc.gov
Complaint

Synda Mark
Attorney
Federal Trade Commission
smark@ftc.gov
Complaint

Maren Schmidt
Attorney
Federal Trade Commission

mschmidt@ftc.gov
Complaint

Eric Sprague
Attorney
Federal Trade Commission
esprague@ftc.gov
Complaint

Jamie Towey
Attorney
Federal Trade Commission
jtowey@ftc.gov
Complaint

Chuck Loughlin
Attorney
Federal Trade Commission
cloughlin@ftc.gov
Complaint

Alpa D. Davis
Attorney
Federal Trade Commission
adavis6@ftc.gov
Complaint

Lauren Peay
Attorney
Federal Trade Commission
lpeay@ftc.gov
Complaint

James H. Weingarten
Attorney
Federal Trade Commission
jweingarten@ftc.gov
Complaint

Edward D. Hassi
O'Melveny & Myers, LLP
ehassi@omm.com
Respondent

Michael E. Antalics
O'Melveny & Myers, LLP
mantalics@omm.com
Respondent

Benjamin J. Hendricks
O'Melveny & Myers, LLP
bhendricks@omm.com
Respondent

Eileen M. Brogan
O'Melveny & Myers, LLP
ebrogan@omm.com
Respondent

Anna Fabish
O'Melveny & Myers, LLP
afabish@omm.com
Respondent

Stephen McIntyre
O'Melveny & Myers, LLP
smcintyre@omm.com
Respondent

Rebecca Weinstein
Attorney
Federal Trade Commission
rweinstein@ftc.gov
Complaint

Garth Huston
Attorney
Federal Trade Commission
ghuston@ftc.gov
Complaint

I hereby certify that on January 04, 2018, I served via other means, as provided in 4.4(b) of the foregoing Complaint Counsel's Exhibit List, upon:

Markus Meier
Attorney
Federal Trade Commission
mmeier@ftc.gov
Complaint

Rebecca Weinstein
Attorney